Gsk Share Discussion Threads

[mcflies] 17/5/2021 11:25

expect the 19p drop on Thursday.

[tradermichael] 17/5/2021 10:53

xd on Thursday?

[xxxxxy] 17/5/2021 09:32

GlaxoSmithKline (GSK.L) and Sanofi (SNY) reported strong results in COVID-19 vaccine trials on Monday morning, saying the jab had "triggered strong neutralising antibody responses in all adult age groups."In an update it said it had found a high immune response after a single dose in patients with prior infection, showing strong booster potential."Overall, the vaccine candidate elicited strong neutralising antibody levels that were comparable to those generated by natural infection, with higher levels observed in younger adults (18 to 59 years old)," it said.Phase 3 trials are expected to start in the coming weeks. The phase 3 trial is expected to enrol more than 35,000 adult participants from a broad range of countries and will assess the efficacy of two vaccine formulations including the D614 (Wuhan) and B.1.351 (South African) variants.GSK is a FTSE 100 (^FTSE) drugs giant worth about £69bn ($97bn) and employing 94,000 people. Despite its size, it has been something of a laggard in the race to produce a coronavirus vaccine, with several other candidates moving to mass-production and worldwide rollout first, including Pfizer (PFE), the Oxford-AstraZeneca (AZN.L) effort and Moderna (MRNA). GSK stock fell around 0.4% in early trade in London on Monday, in line with the rest of the FTSE 100 index. Read more: Ryanair predicts 'strong recovery in air travel' as it suffers €815m loss"The UK continues to see a very smooth and successful rollout of vaccines, but other countries are still playing catch-up or are experiencing supply shortages," said Russ Mould, investment director at AJ Bell. "That's why it could be better late than never for GlaxoSmithKline which has reported encouraging phase 2 results from its joint vaccine candidate with Sanofi."The more vaccines the better, as that would in theory increase the chance for countries around the world to have a fighting chance of tackling COVID and start living lives normally again," Mould continues, noting that the next stage trials could still put a spanner in the works. GSK recently experienced top-level anxiety in its ranks, with 20 shareholders backing the company amid concerns US activist hedge fund Elliott Management was preparing for a shakeup. Institutional shareholders contacted Sir Jonathan Symonds, GSK's chairman to back up the board's current strategy. The rumblings from Elliott Management came amid apparent discontent from other large shareholders. ... Yahoo Finance

[montyhedge] 17/5/2021 09:28

June dividend policy review, I think dividend policy will be the same 80p. With Elliott the hedgie breathing down directors necks, any negative rns, they will be in there demanding GSK broke up, sell off bits, must be valued around 2000p a share.
Pfizer who bid for Astra a couple of years ago, would be straight in there

[tradermichael] 17/5/2021 08:58

Agree! LOL ..... ;0)

[abdullla] 17/5/2021 07:06

This good news deserves a share price drop.

[bountyhunter] 17/5/2021 06:13

Mon, 17th May 2021 06:57Alliance News
(Alliance News)

Sanofi SA and GlaxoSmithKline PLC's adjuvanted recombinant Covid-19 vaccine candidate achieved strong rates of neutralizing antibody responses, the companies reported on Monday.

The interim results showed 95% to 100% seroconversion following a second injection in patients from 18 to 95 years old and across all doses, with acceptable tolerability and with no safety concerns. Overall, the vaccine candidate elicited strong neutralizing antibody levels that were comparable to those generated by natural infection..

[sturichardson] 16/5/2021 21:23

Chuff off.

[williamcooper104] 16/5/2021 19:59

You do indeed get paid for lending out shares - U.K. brokers pocket all of that income for themselves - most American brokers split it with the holder

[williamcooper104] 16/5/2021 19:19

Plus if you are a long term holding then worst that happens is that there's a little extra volatility but you get paid for it

[abdullla] 16/5/2021 19:17

The UK regulator FSA Will never put a ban on shorting,they say they allow this as it provides liquidity in the market for a faster stock movements .

[williamcooper104] 16/5/2021 18:53

But it's a bit stupid not to

[williamcooper104] 16/5/2021 18:53

You don't in the US - hence why GME got to well north of 100 percent short coverage

[dplewis1] 16/5/2021 17:59

I guess that's because you have to have a locate broker in place with the shares before you short in the US so I guess everyone makes more money from the process?

[williamcooper104] 16/5/2021 17:46

I was getting 35 percent borrow fees on one of my US positions - I get peanuts on U.K. stocks

[williamcooper104] 16/5/2021 17:46

It wouldn't - the FTSE is nowhere as heavily shorted as the far more successful US indices are 10 percent short cover is heavily shorted in the U.K. whereas as it often gets up to 30-40 percent in the US

[williamcooper104] 16/5/2021 17:44

My broker allows me to consent and splits the borrow fee with me 50/50 - it takes about 10 percent of the cost of my margin loans

[williamcooper104] 16/5/2021 17:42

Be careful there - there's not one Blackrock entity - it's entirely possible that one Blackrock vehicle is short and another one is long

[spud] 16/5/2021 17:39

It is thought that Elliott could take aim at the drug maker's chief executive Emma Walmsley over concerns about her leadership and lack of a scientific background.Fire away as far as I'm concerned! spud

[whatsup32] 16/5/2021 17:33

Activist investor Elliott warns GSK investors ‘change is coming’